PIK3CA, on the other hand, is commonly mutated in both early neoplasias (approximately 50%) [8] and ER+/luminal breast cancers (approximately 20%) [1] but does not show significant expression changes in the early neoplasias. Here, ESR1 is linked to breast cancer.